|
Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial
|
3
|
Zenith Epigenetics
|
Sep 03, 2018 11:22PM
|
|
Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial
|
3
|
Zenith Epigenetics
|
Sep 03, 2018 12:50AM
|
|
Re: UpComing Catalyst(s)
|
5
|
Resverlogix Corp.
|
Nov 11, 2020 11:05PM
|
|
Re: Upcoming Dimentia news in early Dec
|
4
|
Resverlogix Corp.
|
Nov 05, 2019 03:21AM
|
|
Re: Update
|
2
|
Resverlogix Corp.
|
Feb 14, 2018 04:50AM
|
|
Re: Update
|
4
|
Resverlogix Corp.
|
Jun 12, 2019 09:33AM
|
|
Re: Updated Analyst Report from Marcel Wijma, Van Leeuwenhoeck Institute
|
6
|
Resverlogix Corp.
|
Feb 02, 2018 12:37PM
|
|
Re: Updated List of BET inhibitors
|
5
|
Zenith Epigenetics
|
Apr 10, 2019 03:27PM
|
|
Re: Updated Van Leeuwenhoeck Analyst Report by Marcel Wijma 5/2/2019
|
4
|
Resverlogix Corp.
|
May 03, 2019 08:09AM
|
|
Re: Updated Van Leeuwenhoeck Analyst Report by Marcel Wijma 5/2/2019
|
3
|
Resverlogix Corp.
|
May 03, 2019 01:55PM
|
|
Re: Updated Van Leeuwenhoeck Analyst Report by Marcel Wijma 5/2/2019
|
2
|
Resverlogix Corp.
|
May 03, 2019 02:15PM
|
|
Re: Updated Van Leeuwenhoeck Analyst Report by Marcel Wijma 5/2/2019
|
3
|
Resverlogix Corp.
|
May 03, 2019 04:48PM
|
|
Re: US 2017 Tax Cuts and Jobs Act
|
2
|
Resverlogix Corp.
|
Dec 21, 2017 08:52PM
|
|
Re: US to shell out $1.2B for supplies of Merck's potential Covid-19 antiviral.
|
8
|
Resverlogix Corp.
|
Jun 10, 2021 01:02PM
|
|
Re: US to shell out $1.2B for supplies of Merck's potential Covid-19 antiviral.
|
3
|
Resverlogix Corp.
|
Jun 10, 2021 02:46PM
|
|
Re: USA ZHCLF investors
|
4
|
Zenith Epigenetics
|
Nov 02, 2022 02:36PM
|
|
Re: USA ZHCLF investors
|
1
|
Zenith Epigenetics
|
Nov 02, 2022 09:41PM
|
|
Re: USA ZHCLF investors
|
1
|
Zenith Epigenetics
|
Nov 01, 2022 12:02PM
|
|
Re: USA ZHCLF investors
|
2
|
Zenith Epigenetics
|
Oct 28, 2022 10:15PM
|
|
Re: UW nanoparticle vs C19
|
3
|
Resverlogix Corp.
|
Nov 03, 2020 12:00PM
|
